GPC Enzymes: Breakdown of Phospholipid Membranes and Potential Drug Targets

Target Name: GLYATL3

NCBI ID: G389396

GLYATL3

GPC Enzymes: Breakdown of Phospholipid Membranes and Potential Drug Targets

GLYATL3 (bA28H17.2) is a protein that is expressed in various tissues of the body, including the brain, heart, and kidneys. It is a member of the Glycophosphorylase (GPC) family, which is a group of enzymes that involved in the breakdown of glycophospholipids. GPC enzymes are important for the proper functioning of various cell types, including neurons and immune cells.

One of the functions of GPC enzymes is to break down the phosphatidylcholine (PC) molecule, which is a key component of cell membranes. PC is also known as phospholipid A2 (PLA2), and it is important for the formation and maintenance of the cell membrane. When GPC enzymes break down PC, they produce a phospholipid fragment that can be used to form new cell membranes or to contribute to the repair of existing membranes.

GPC enzymes have been implicated in the development and progression of a number of diseases, including heart disease, diabetes, and neurodegenerative disorders. For example, studies have shown that GPC enzymes are overexpressed in the brains of individuals with Alzheimer's disease, and that they are also elevated in the blood of individuals with diabetes.

In addition to their role in the formation and maintenance of cell membranes, GPC enzymes may also be involved in the regulation of various cellular processes. For example, GPC enzymes have been shown to be involved in the production of reactive oxygen species (ROS), which can damage cellular components and contribute to the aging process.

GPC enzymes are also potential drug targets. Researchers are currently exploring the use of GPC enzyme inhibitors as a treatment for a variety of conditions, including heart disease, diabetes, and neurodegenerative disorders. These inhibitors can be used to reduce the production of PC by GPC enzymes, which can lead to the formation of new cell membranes and improve the function of existing membranes.

In addition to their potential use as a drug, GPC enzymes are also being investigated as a biomarker for various diseases. For example, GPC enzyme levels have been shown to be elevated in the brains of individuals with Alzheimer's disease, and they may be a useful diagnostic marker for this condition. Similarly, GPC enzyme levels have been shown to be elevated in the blood of individuals with diabetes, and they may be a useful biomarker for this disease.

Overall, GPC enzymes are a fascinating group of enzymes that are involved in the breakdown of crucial cellular components. While they have been implicated in the development and progression of many diseases, they are also potential drug targets and biomarkers. Further research is needed to fully understand the role of GPC enzymes in the body and to develop effective treatments for the various conditions in which they are involved.

Protein Name: Glycine-N-acyltransferase Like 3

Functions: Catalyzes the conjugation of long-chain fatty acyl-CoA thioester and glycine to produce long-chain N-(fatty acyl)glycine, an intermediate in the primary fatty acid amide biosynthetic pathway

The "GLYATL3 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about GLYATL3 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets